The relative risk caused by RAD51C mutations has been estimated higher for ovarian cancer (risk ratio 7.55) than it is for breast cancer (risk ratio 1.99), which places RAD51C in the category of moderate-risk genes [28]. This evidence concerns the gene RAD51C and breast cancer.